Effectiveness and satisfaction with zolmitriptan 5mg nasal spray for treatment of migraine in real-life practice: Results of a postmarketing surveillance study

Clinical Drug Investigation

Volumn 27, Issue 1, 2007, Pages 59-66

  Diener, Hans Christoph ^a   Evers, Stefan ^b  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ZOLMITRIPTAN;

ADULT; ANGINA PECTORIS; ARTICLE; ASTHENIA; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DEPRESSION; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; EPISTAXIS; FEMALE; FOLLOW UP; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MEDICAL PRACTICE; MIGRAINE; NAUSEA; PARESTHESIA; PATIENT SATISFACTION; PHARYNGITIS; PHONOPHOBIA; PHOTOPHOBIA; PHYSICIAN; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RHINITIS; SIDE EFFECT; TREATMENT OUTCOME; VOMITING;

EID: 33846087513     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200727010-00005     Document Type: Article

References (21)

1. Gladstone J, Gawel M. Newer formulations of the triptans: advances in migraine management. Drugs 2003; 63: 2285-305
2. Rapoport AM, Tepper SJ, Bigal ME, et al. The triptan formulations: how to match patients and products. CNS Drugs 2003; 17: 431-47
3. Stang PE, Von Korff M. The diagnosis of headache in primary care: factors in the agreement of clinical and standardized diagnoses. Headache 1994; 34: 138-42
4. Lipton RB, Stewart WF, Simon D. Medical consultation for migraine: results from the American Migraine Study. Headache 1998; 38: 87-96
5. MacGregor A, Brandes J, Eikermann A. Migraine prevalence and treatment patterns: the global Migraine and Zolmitriptan Evaluation survey. Headache 2003; 43: 19-26
6. Hu XH, O'Donnell F, Kunkell RS, et al. Survey of migraineurs referred to headache specialists: care, satisfaction, and outcomes. Neurology 2000; 55: 141-3
7. Sculpher M, Millson D, Meddis D, et al. Cost-effectiveness analysis of stratified versus stepped care strategies for acute treatment of migraine: the Disability in Strategies for Care (DISC) study. Pharmacoeconomics 2002; 20: 91-100
8. MacGregor A, Brandes J, Gendolla A, et al. Migraine treatment strategies: the global Migraine and Zolmitriptan Evaluation (MAZE) survey - phase IV. Curr Med Res Opin 2004; 20: 1777-83
9. MacGregor A, Brandes J, Eikermann A, et al. Impact of migraine on patients and their families: the Migraine and Zolmitriptan Evaluation (MAZE) survey: phase III. Curr Med Res Opin 2004; 20: 1143-50
10. Malik SN, Hopkins M, Young WB, et al. Acute migraine treatment: patterns of use and satisfaction in a clinical population. Headache 2006; 46: 773-80
11. Lipton RB, Hamelsky SW, Dayno JM. What do patients with migraine want from acute migraine treatment? Headache 2002; 42 Suppl. 1: 3-9
12. Charlesworth BR, Dowson AJ, Purdy A, et al. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine. CNS Drugs 2003; 17: 653-67
13. Dowson A, Charlesworth B, Purdy A, et al. Tolerability and consistency of effect of zolmitriptan nasal spray in a long-term migraine treatment trial. CNS Drugs 2003; 17: 839-51
14. Dodick D, Brandes J, Elkind A, et al. Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the management of acute migraine: a randomised, double-blind, placebo-controlled study. CNS Drugs 2005; 19: 125-36
15. Dowson AJ, Charlesworth BR, Green J, et al. Zolmitriptan nasal spray exhibits good long-term safety and tolerability in migraine: results of the INDEX trial. Headache 2005; 45: 17-24
16. Gawel M, Aschoff J, May A, et al. Zolmitriptan 5mg nasal spray: efficacy and onset of action in the acute treatment of migraine: results from phase I of the REALIZE study. Headache 2005; 45: 7-16
17. Gawel M, Aschoff J, May A, et al. Treatment satisfaction with zolmitriptan nasal spray for migraine in a real life setting: results from phase II of the REALIZE study. J Headache Pain 2005; 6: 405-11
18. Uemura N, Onishi T, Mitaniyama A, et al. Bioequivalence and rapid absorption of zolmitriptan nasal spray compared with oral tablets in healthy Japanese subjects. Clin Drug Invest 2005; 25: 199-208
19. Wall A, Kågedal M, Bergström M, et al. Distribution of zolmitriptan into the CNS in healthy volunteers: a positron emission tomography study. Drugs R and D 2005; 6: 139-47
20. Dahlöf C, Linde M, Kerekes E. Zolmitriptan nasal spray provides fast relief of migraine symptoms and is preferred by patients: a Swedish study of preference in clinical practice. J Headache Pain 2004; 5: 237-42
21. Boes Hansen S. Effectiveness and patient satisfaction with zolmitriptan nasal spray 5 mg in clinical practice: a patient survey. Headache Care 2005; 2: 127-32